BDWM
CRL icon

Brewin Dolphin Wealth Management’s Charles River Laboratories CRL Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$14K Hold
65
– – ﹤0.01% 267
2022
Q1 		$18K Hold
65
– – ﹤0.01% 259
2021
Q4 		$24K Buy
+65
New +$25.3K ﹤0.01% 245

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brewin Dolphin Wealth Management's CRL Position: Q2 2022 in Review

Brewin Dolphin Wealth Management held its Charles River Laboratories (CRL) position steady in Q2 2022 at 65 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #267.

Brewin Dolphin Wealth Management first reported a position in CRL in Q4 2021 and has held it in 3 quarters since. The position peaked at $24K in Q4 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

  • Brewin Dolphin Wealth Management held 65 shares of Charles River Laboratories worth $14K as of Q2 2022.
  • Brewin Dolphin Wealth Management left its Charles River Laboratories share count unchanged in Q2 2022.
  • Charles River Laboratories made up ﹤0.01% of Brewin Dolphin Wealth Management's portfolio in Q2 2022, its #267 holding.
  • Brewin Dolphin Wealth Management first reported a position in Charles River Laboratories in Q4 2021 and has held it in 3 quarters since.
  • Brewin Dolphin Wealth Management's Charles River Laboratories position peaked at $24K in Q4 2021.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.